Evidence map›Paper›PMID 41438130›Full record

ReviewMolecular therapy. Oncology2025

Viral warriors: Unlocking the immune system's potential with oncolytic viruses in cancer immunotherapy.

Reza Ghavimi, Leila Rahimian, Mohsen Mohammadi, Ojasvi Dutta, Harikrishnan Mohan, Vladimir Chouljenko, Tolulope O Omolekan, Jean Christopher Chamcheu, Konstantin G Kousoulas

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Molecular therapy. Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Tuning epigenetics to enhance cancer virotherapy.Acta pharmaceutica Sinica. B · 2026
    Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Reza GhavimiDepartment of Pathobiological Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, LA 70803, USA.
Leila RahimianDepartment of Pathobiological Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, LA 70803, USA.
Mohsen MohammadiDepartment of Immunology, School of Medicine, University of Pittsburgh, Pittsburgh, PA 15213, USA.
Ojasvi DuttaDepartment of Pathobiological Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, LA 70803, USA.
Harikrishnan MohanDepartment of Pathobiological Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, LA 70803, USA.
Vladimir ChouljenkoDepartment of Pathobiological Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, LA 70803, USA.
Tolulope O OmolekanDepartment of Pathobiological Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, LA 70803, USA.
Jean Christopher ChamcheuDepartment of Pathobiological Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, LA 70803, USA.
Konstantin G KousoulasDepartment of Pathobiological Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, LA 70803, USA.

Funding

Harnessing the potential of pharmacological small molecules to amplify VSV-based oncolytic viral therapyR15CA290568 · NCI · SOUTHERN UNIV A&M COL BATON ROUGE · PI CHAMCHEU, JEAN CHRISTOPHER · 2024 to 2024
$409k
NCI NIH HHS R15 CA290568
6 · The paper itself

Abstract

Oncolytic viruses (OVs) represent an exciting avenue in tumor immunotherapy, harnessing the power of viruses to overcome resistance and enhance immune responses. OVs achieve this by selectively targeting and destroying tumor cells. This cell lysis releases tumor-specific antigens (TAAs), effectively creating an

Indexed as

antitumor immunitycancercombination immunotherapyimmuno-oncologyMT: Regular Issueoncolytic virustargeted therapytumor

Identifiers

PMID41438130
PMCPMC12721169

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.